Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment-Reference-Cited by-同舟云学术

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Published:2022-01-21 Issue:5 Volume:24 Page:806-815
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Meier Juris J.¹²^ORCID,Quast Daniel R.¹^ORCID,Nauck Michael A.¹^ORCID,Schenker Nina¹,Deacon Carolyn F.³^ORCID,Holst Jens J.³,Plum‐Mörschel Leona⁴,Kapitza Christoph⁵^ORCID

Affiliation:

1. Diabetes Division, St Josef‐Hospital Ruhr‐University Bochum Bochum Germany

2. Department of Internal Medicine, Gastroenterology and Diabetes Augusta Clinic Bochum Bochum Germany

3. Department of Biomedical Sciences and NovoNordisk Centre for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen, Panum Institute Copenhagen Denmark

4. Profil Mainz Germany

5. Profil Neuss Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14636

Reference47 articles.

1. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease

2. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia

3. Diabetic Kidney Disease

4. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

5. Glucagon-like peptide 1 (GLP-1)